From ACC '09: Dr. Bhatt's thoughts on the evolution of the Reach Registry and long term expectations


  • Deepak Bhatt, MD
    Chief of Cardiology
    VA Boston Healthcare System and Brigham and Women's Hospital,
    Boston, Massachusetts;
    TIMI Study Group Harvard Medical School
    Boston, Massachusetts.




Tune into Dr Hirsch as he discusses PAD and polyvascular disease


  • Alan T. Hirsch, MD
    Director, Vascular Medicine Program
    Minneapolis Heart Institute
    Abbott Northwestern's Vascular Center
    Minneapolis, MN



Access interviews from Drs Goto and Mahoney to get their perspectives on the registry.



pdf Krempf M et al. Cardiovascular Event Rates in Diabetic and Nondiabetic Individuals With and Without Established Atherothrombosis (From the REduction of Atherothrombosis for Continued Health [REACH] Registry). Am J Cardiol 2010;105(5):667-671.

pdf Ducrocq G et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J 2010 [Free to access]

pdf Meadows TA et al. Ethnic Differences in the Prevalence and Treatment of Cardiovascular Risk Factors in US Outpatients with Peripheral Arterial Disease: Insights from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Am Heart J 2009;158:1038-1045.

pdf Dumaine RL et al. Renal function, atherothrombosis extent, and outcomes in high-risk patients. Am Heart J. 2009;158(1):141-148.e1.

pdf Alberts MJ et al. Three-year follow-up and event rates in the international Reduction of atherothrombosis for Continued Health Registry. Eur Heart J. 2009;30:2318-26. [Free to access]

pdf Aichner FT et al. High cardiovascular event rates in patients with asymptomatic carotid stenosis: the REACH registry. Eur J Neurol. 009;16:902-8

pdf Cacoub PP et al. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis. 2009;204(2):e86-92.

pdf Weimar C et al. The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for Continued Health (REACH) registry. Stroke. 2009;40(2):350-4. [Free to access]

pdf Baumgartner I, et al. Cardiovascular risk profile and outcome of patients with abdominal aortic aneurysm in out-patients with atherothrombosis: Data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. J Vasc Surg . 2008;48:808-14.

pdf Goto S, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008;156:855-863.

Steg

Dr Joachim Röther discusses the the two-year analysis

Explore the intriguing recent data with Dr Röther, on the management and outcomes of patients with, or at high risk of, atherothrombosis.



pdf Röther J et al. Two-year cardiovascular event rates of the cerebrovascular disease subpopulation within the REACH Registry Presented by Joachim Röther at the 2008 European Stroke Congress (Nice, France). [PDF - 94 KB]


Access interviews from Drs Bhatt, Steg, Ohman and Alberts to get their perspectives on the registry.





Steg

The importance of the REACH registry

Dr Gabriel Steg, Co-chair with Dr Deepak Bhatt of the REACH registry, outlines the essential information you need to know about this landmark registry of over 68 000 patients with atherothrombosis.



Bhatt

The REACH Registry: Results and implications

Dr Deepak Bhatt brings you up to date on the published and upcoming research from the Registry that will affect your practice.




PieChart

One-year data results

High rates of MI or stroke were found in REACH Registry patients, especially in those with atherothrombosis in multiple beds, whether or not they were symptomatic. This suggests that "atherothrombosis should be addressed as a global arterial disease," note Dr Ph Gabriel Steg and colleagues.

View the abstract to the paper, published in JAMA, and download the comprehensive slide kit (members only).



The REACH registry is a worldwide health survey and one of the biggest international epidemiological registries to date. Over 68 000 people worldwide are now participating, representing the entire spectrum of those at risk.

One-year follow-up data results have been published, and the overall retention rate after two years of follow-up has been very successful.




sponsored by
sanofi aventis BMS
text
 
NEW! Publications section
Interested in results from REACH Registry studies? Visit the Publications section for a complete listing of global and local articles.
NEW! Investigators Update
Don't miss the latest issue of the REACH registry bulletin Investigators Update, formerly known as The Observer.
Webcast
View the video proceedings of the Regional Investigator Meeting, held on 15 March in Chicago, IL, with special guest Dr Mark Alberts.